Evaluation of autoreceptor-mediated control of [3H]acetylcholine release in rat and human neocortex

Experimental Brain Research

Volumn 128, Issue 3, 1999, Pages 383-389

  Albrecht, C ^a   Bloss, H G ^a   Jackisch, R ^b   Feuerstein, T J ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Acetylcholine release; Alzheimer's disease; Autoinhibition; Human neocortex; Rat neocortex

Indexed keywords

ACETYLCHOLINE; ACETYLCHOLINESTERASE; ATROPINE; AUTORECEPTOR; CHOLINE; OXOTREMORINE;

ACETYLCHOLINE RELEASE; ADULT; ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ELECTROSTIMULATION; FEEDBACK SYSTEM; FEMALE; HUMAN; HUMAN TISSUE; MALE; NEOCORTEX; NONHUMAN; PRIORITY JOURNAL; RAT;

ACETYLCHOLINE; AGED; ALZHEIMER DISEASE; ANIMALS; ATROPINE; CARRIER PROTEINS; ELECTRIC STIMULATION; FEMALE; HUMANS; MALE; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; MUSCARINIC AGONISTS; MUSCARINIC ANTAGONISTS; NEOCORTEX; OXOTREMORINE; RATS; SYNAPTIC TRANSMISSION; VESICULAR ACETYLCHOLINE TRANSPORT PROTEINS; VESICULAR TRANSPORT PROTEINS;

EID: 0032874712     PISSN: 00144819     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002210050858     Document Type: Article

References (23)

1. Agneter E, Singer EA, Sauermann W, Feuerstein TJ (1997) The slope parameter of concentration-response curves used as touchstone for the existence of spare receptors. Naunyn-Schmiedeberg's Arch Pharmacol 356: 283-292
2. Buyukuysal RL, Wurtman RJ (1990) 4-Aminopyridine increases acetylcholine release without diminishing membrane phosphatidylcholine. J Neurochem 54: 1302-1309
3. Canal N, Imbimbo BP (1996) Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease. Eptastigmine Study Group. Clin Pharmacol Ther 60: 218-228
4. Cho AK, Haslett WL, Jenden DL (1962) The peripheral actions of oxotremorine, a metabolite of tremorine. J Pharmacol Exp Ther 138: 249-257
5. Coyle JT, Price DL, DeLong MR (1 983) Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 219: 1184-1190
6. Detari L, Vanderwolf CH (1987) Activity of identified cortically projecting and other basal forebrain neurones during large slow waves and cortical activation in anaesthetized rats. Brain Res 437: 1-8
7. Feuerstein TJ, Limberger N (1999) Mathematical analysis of the control of neurotransmitter release by presynaptic receptors as a supplement to experimental data. Naunyn-Schmiedeberg's Arch Pharmacol 359: 349-359
8. Feuerstein TJ, Seeger W (1997) Modulation of acetylcholine release in human cortical slices: possible implications for Alzheimer's disease. Pharmacol Ther 74: 333-347
9. Feuerstein TJ, Bammert J, Meyer DK (1987) Endogenous agonists may change the concentration-response curves of exogenous agonists: source of quantitative information about the endogenous tone. Biol Cybern 56: 419-429
10. Feuerstein TJ, Dooley DJ, Seeger W (1990) Inhibition of norepinephrine and acetylcholine release from human neocortex by co-conotoxin GVIA. J Pharmacol Exp Ther 252: 778-785
11. Feuerstein TJ, Lehmann J, Sauermann W, van Velthoven V, Jackisch R (1992) The autoinhibitory feedback control of acetylcholine release in human neocortex tissue. Brain Res 572:64-71
12. Feuerstein TJ, Sauermann W, Allgaier C, Singer EA (1993) Mathematical modelling and quantification of the autoinhibitory feedback control of noradrenaline release in brain slices. Naunyn-Schmiedeberg's Arch Pharmacol 347: 171-179
13. Feuerstein TJ, Rossner R, Schumacher M (1997) How to express an effect mean as percentage of a control mean? J Pharmacol Toxicol Meth 37: 187-190
14. Geula C, Mesulam MM (1995) Cholinesterases and the pathology of Alzheimer disease. Alzheimer Dis Assoc Disord 9 [Suppl] 2: 23-28
15. Grimm U, Moser U, Mutschler E, Lambrecht G (1994) Muscarinic receptors: focus on presynaptic mechanisms and recently developed novel agonists and antagonists. Pharmazie 49: 711-726
16. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI (1994) A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. JAMA 271: 985-991
17. Marchi M, Raiteri M (1996) Nicotinic autoreceptors mediating enhancement of acetylcholine release become operative in conditions of "impaired" cholinergic presynaptic function. J Neurochem 67: 1974-1981
18. 2 muscarine receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation. Science 228: 1115-1117
19. Matthews RT, Lee WL (1991) A comparison of extracellular and intracellular recordings from medial septum/diagonal band neurons in vitro. Neurosci 42: 451-462
20. 3H-acetylcholine from rat cerebral cortex slices in vitro. Br J Pharmacol 47: 97-108
21. Quirion R, Aubert I, Lapchak PA, Schaum RP, Teolis S, Gauthier S, Araujo DM (1989) Muscarinic receptor subtypes in human neurodegenerative disorders: focus on Alzheimer's disease. Trends Pharmacol Sci [Suppl] 12: 80-84
22. Richardson IW, Szerb JC (1974) The release of labelled acetylcholine and choline from cerebral cortical slices stimulated electrically. Br J Pharmacol 52: 499-507
23. Sugaya K, Clamp C, Bryan D, McKinney M (1997) mRNA for the m4 muscarinic receptor subtype is expressed in adult rat brain cholinergic neurons. Mol Brain Res 50: 305-313